Pet Cancer Options

Evidence-Based Treatment Guide

v2.0.0

Your cat was diagnosed with Mast Cell Tumour, Splenic/Visceral. Aggressive presentation. Third most common intestinal tumour in cats. Median age ~10 years (reported in literature). Male sex reported as negative prognostic factor (Evans et al. 2017), consistent with possible male predisposition, though dedicated epidemiological study is lacking. Compare 11 treatment options for cats including Splenectomy, Splenectomy + Chemotherapy, Lomustine — with survival times, costs, and what to expect during treatment.

Pet Cancer Options — Mast Cell Tumour, Splenic/Visceral

Feline Oncology Treatment Guide

🐈

Mast Cell Tumour, Splenic/Visceral

feline

Round Cell

About This Cancer

Visceral (internal organ) mast cell tumours in cats are a far more serious disease than the cutaneous form. The most common presentation involves the spleen, where massive mast cell infiltration can occur, sometimes also affecting the liver, intestines, and bone marrow. It is the third most common intestinal tumour in cats. Unlike the generally benign cutaneous mast cell tumour in cats, visceral mast cell disease is aggressive and carries a more guarded prognosis. The release of histamine and other chemicals from the mast cell granules can cause gastrointestinal ulceration, vomiting, and loss of appetite. Splenectomy (removal of the spleen) is a key component of treatment and can significantly improve survival, with some cats doing well for extended periods after surgery, especially when the disease is primarily splenic.

Practical Staging for Feline Splenic/Visceral MCT

No formally validated staging system exists for feline splenic/visceral MCT. This practical staging scheme is derived from clinical behaviour patterns described in the literature.

Stage Stage ISplenic involvement only. No hepatic or distant metastasis. Best prognosis with splenectomy (MST ~856 days).

Stage Stage IISplenic + hepatic involvement. Intermediate prognosis.

Stage Stage IIIDistant metastasis (peritoneal carcinomatosis, bone marrow involvement, or widespread visceral disease). Worst prognosis.

Prognostic Factors(9)

AnorexiaPresence worse prognosis(Evans et al., 2017 (PMID 28168776) — univariate analysis found NONE of these variables significantly affected survival (Evans et al. 2017, n=64); underpowered study)

Male sexWorse prognosis than female(Evans et al., 2017 (PMID 28168776) — reported as negative prognostic factor; univariate analysis found NONE of these variables significantly affected survival (n=64); study likely underpowered)

Weight lossNegative prognostic indicator(Evans et al., 2017 (PMID 28168776) — univariate analysis found NONE of these variables significantly affected survival (Evans et al. 2017, n=64); underpowered study)

Metastatic diseaseSignificantly worse outcome(Evans et al., 2017 (PMID 28168776) — univariate analysis found NONE of these variables significantly affected survival (Evans et al. 2017, n=64); underpowered study)

Need for transfusionIndicates severe disease(Evans et al., 2017 (PMID 28168776) — univariate analysis found NONE of these variables significantly affected survival (Evans et al. 2017, n=64); underpowered study)

Mitotic indexHigher mitotic index associated with more aggressive behaviour and shorter survival in mast cell tumours generally. Specific cutoffs for feline splenic MCT not well-established.(General MCT literature — no feline splenic MCT-specific study identified)

c-Kit mutation status (exon 8 ITDs)Internal tandem duplications in exon 8 of c-Kit are found in a subset of feline MCT and may predict response to tyrosine kinase inhibitors (toceranib). Prognostic significance in feline splenic MCT specifically is not well-characterised.(Berger et al., 2018 (PMID 29172873) — toceranib evaluation in feline MCT documents c-Kit relevance)

Mitotic indexHigher mitotic index associated with more aggressive behaviour and worse prognosis in feline MCT. Threshold for significance in splenic MCT not firmly established.(General histopathological principle; no splenic-MCT-specific study identified)

c-Kit mutation status (exon 8 ITDs)Exon 8 internal tandem duplications in c-Kit identified in feline MCT. May predict response to tyrosine kinase inhibitors (toceranib). Prognostic significance in splenic/visceral form specifically is not well-characterised.(Isotani et al., 2006 (PMID 16644932) — identified c-Kit mutations in feline MCT; visceral-specific prognostic data limited)

Minimum Workup(9 steps)

1CBC (including differential, buffy coat evaluation)

2Serum chemistry and coagulation profile

3Bone marrow aspirate (assess for systemic involvement)

4Thoracic radiographs (pleural effusion assessment)

5Abdominal ultrasound (hepatosplenomegaly, nodal changes)

6Liver and spleen aspirates (if imaging abnormal)

7Regional lymph node sampling (if enlarged)

8FNA cytology of primary lesion

9CRITICAL: Antihistamine premedication before sampling (anaphylaxis risk from mast cell degranulation)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength

Splenectomy

~28.5 mo

Strong

$3,000–$5,500

Splenectomy + Chemotherapy

~28.4 mo

Moderate

$4,500–$7,500

Lomustine

See notes

Moderate

$200–$400

Toceranib

See notes

Moderate

$300–$600

Supportive Care Only

~11.4 mo

Moderate

$50–$200

Chlorambucil-Based Chemotherapy

See notes

Indirect

$100–$300

Prednisolone Monotherapy

See notes

Indirect

$20–$50

Vinblastine (Rescue)

See notes

Indirect

$200–$400

Chlorambucil-Based Chemotherapy

See notes

Indirect

$100–$300

Prednisolone Monotherapy

See notes

Indirect

$20–$60

Vinblastine (Rescue/Relapse)

See notes

Indirect

$200–$400

Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.

Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.

ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.

IndirectEvidence comes from a different tumour type or species and has been applied here.

LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.

Pet Cancer Options — Mast Cell Tumour, Splenic/Visceral

Mast Cell Tumour, Splenic/Visceral

Median Survival Time Comparison

Splenectomy

Splenectomy + Chemotherapy

Lomustine

Toceranib

Supportive Care Only

Chlorambucil-Based Chemotherapy

Prednisolone Monotherapy

Vinblastine (Rescue)

Chlorambucil-Based Chemotherapy

Prednisolone Monotherapy

Vinblastine (Rescue/Relapse)

Related Diagnoses